Christopher Martell, Director at Candel Therapeutics, Inc. (CADL), bought 27,000 shares at $1.68 ($51K) on 2022-12-08, disclosed to the SEC on 2022-12-12.
Open-market purchase of $51k CADL by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.68 | 3,050 | $5K | 10.0% |
| 2 | $1.92 | 23,950 | $46K | 90.0% |
| Total | $1.89 avg | 27,000 | $51K | 100% |